Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sichuan Baili Pharm Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is overseen by 1 distinct examiner and 1 distinct art unit, focusing the company's current office activity. This level of focus suggests that the company is prioritizing a specific pharmaceutical advancement in its active docket. The pending office action represents the current focus of the company's intellectual property development.
The busiest examiner for the portfolio is ESSEX, LAURA ANN, who handles 1 busiest examiner pending office action. The outcome of the company's active docket is subject to the specific examination practices of this official. Practitioners should evaluate the examiner's previous rulings in the Biotechnology & Pharmaceuticals field to prepare effective responses. The success of the 1 pending office action will determine the company's immediate progress in securing patent rights. Navigating the requirements of this specific examiner is the most critical task for the company's current prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESSEX, LAURA ANN | 1 | 60.5% | +35.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18008798 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | ESSEX, LAURA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18008798 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | ESSEX, LAURA ANN | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18008798 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | ESSEX, LAURA ANN | 1675 | §102§103§112 | Non-Final OA | — | Pending | Dec 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial